side-effectsMay 11, 2026·4 min read

CJC-1295 Side Effects: Phase 2 Trial Data Breakdown

Injection-site reactions lead. Flushing and fluid retention cluster in community reports. Full safety breakdown.

Save

CJC-1295 side effects from Phase 1/2 trial and community data

CJC-1295 is a GHRH analog with published Phase 1 and Phase 2 data in healthy adults (Teichman et al., PMID 16352683; Jetté et al., PMID 15817669). The non-DAC version provides pulsatile stimulation; the DAC-modified version covalently binds endogenous albumin, extending half-life to 5-8 days for sustained GH/IGF-1 elevation. Both forms share an adverse-event profile dominated by injection-site reactions and brief flushing.

Research-context information only. CJC-1295 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

This article walks through the Phase 1/2 trial findings, separates non-DAC from DAC-version event patterns, and describes the community self-reported adverse events for both.

Trial-Reported Adverse Events

From Phase 1 and 2 work (Teichman et al., PMID 16352683):

Event Frequency in active arm Source
Injection-site erythema ~15% PMID 16352683
Facial flushing post-injection ~10% PMID 16352683
Headache 5-10% PMID 16352683
IGF-1 elevation 1.5-3x baseline Pharmacologic finding PMID 16352683
Serious adverse events None reported PMID 16352683

The published trials enrolled adults aged 21-61 years across 28-day and 49-day protocols. They were dose-finding studies, not pivotal Phase 3 trials, and were not designed to detect rare adverse events.

CategoryGrowth & Repair Peptides
ClassGH secretagogue
GoalMuscle Growth
Best Kit Deal10-VialCOASave 36%

Ion Peptide — 10mg × 10 (100mg) — $368 $312 with code thepeptidecatalog (15% off) ($3.12/mg)

Top CJC-1295 Vendors

Ranked by price, COA availability, and reputation

1
EZ PeptidesCOA
10/10
5mg$7.60/mg
2
Nura PeptidePREMIUMCOA
9.8/10
5mg$15.60/mg
3
Ascension PeptidesCOA
9.5/10
$8.00/mg
See full vendor rankings for CJC-1295 →

IGF-1 Elevation as a Pharmacologic Signal

CJC-1295's GHRH agonism produces dose-proportional GH elevation, which raises IGF-1. The 1.5-3x baseline IGF-1 elevation in trial reports is the pharmacologic mechanism, not an adverse event per se — but it informs the monitoring pattern community sources commonly describe.

FDA labeling for the related tesamorelin product recommends IGF-1 monitoring. Community sources for CJC-1295 commonly describe IGF-1 measurement at baseline, 4-8 weeks, and 16-24 weeks; dose reduction is described when IGF-1 exceeds the lab's upper reference range.

CJC-1295 trial adverse event chart

Self-Reported Community Adverse Events

Note on labeling: the events below come from r/peptides, r/PeptideTherapy, and peptide forums for subcutaneous CJC-1295 use (both DAC and non-DAC versions).

Injection-site reactions

The most consistent community feedback. Mild redness, itching, or a small welt at the subcutaneous injection site, typically lasting under 24 hours.

Facial flushing within 10-20 minutes

Community sources commonly describe a brief warmth and visible flush after subcutaneous injection, particularly in the first weeks of use. Self-reported community sources describe injection-site rotation and slower injection speeds reducing severity.

Hand or face fluid retention

Self-reported community timelines describe mild fluid retention — particularly noticeable in the hands and around the face — during the first 2-4 weeks at higher doses. The pattern is more pronounced with CJC-1295 with DAC and resolves with dose reduction or cycling.

Hand tingling or numbness

Community reports cluster around transient hand tingling at higher doses, attributed by community sources to GH-induced fluid retention causing median-nerve compression. This is a documented GH-pharmacology finding (carpal tunnel-pattern symptoms in tesamorelin Phase 3 — see tesamorelin side effects).

Vivid dreams or sleep changes

Most consistent community feedback for evening administration is vivid dreams or restless sleep in the first week. Some users describe deeper sleep; others describe early-morning waking.

DAC vs Non-DAC Differences in Community Reports

Pattern CJC-1295 non-DAC (modified GRF 1-29) CJC-1295 with DAC
GH/IGF-1 elevation Pulsatile (hours) Sustained (5-8 days)
Water retention reports Less common More common
Hand tingling Less common More common
Sleep disruption Less common More common
Cycle length community-typical Continuous daily 1-2x weekly

The DAC version's longer half-life produces a different exposure pattern, which maps to a different community-reported event profile.

Dose-Response Patterns

Phase 1/2 trials tested CJC-1295 with DAC at single doses ranging from 30-250 mcg/kg (PMID 16352683). Dose-proportional GH and IGF-1 elevation was observed across that range. Community-reported research-peptide doses cluster around 100-300 mcg per dose (non-DAC, daily or twice-daily) or 1-2 mg per dose (DAC, 1-2x weekly).

Self-reported community sources describe injection-site reactions and fluid retention scaling with daily dose; serious events remain rare in community reports at typical doses.

30ml bacteriostatic water vial — 0.9% benzyl alcohol multi-dose
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
See why our bac water doesn't ruin peptides
30ml from $18.75 · Ships fast · Code thepeptidecatalog

Dose-Pause and Discontinuation Patterns

Phase 1/2 protocols allowed dose-interruption for severe injection-site reactions, IGF-1 elevations above protocol thresholds, and protocol-defined laboratory abnormalities. Community sources describe two patterns. Pause-and-resume — short breaks when hand-tingling or fluid retention becomes intrusive. Dose-cycling — 8-12 weeks on, 4 weeks off, citing IGF-1 normalization during off-cycles.

CJC-1295 mechanism and tissue effect map

Core Supplies for This Protocol

The essentials for running any reconstituted injectable: cold storage, accurate syringes, alcohol prep pads, and metabolic tracking.

Cooluli Classic 4L Mini Fridge
Storage

Cooluli Classic 4L Mini Fridge

Compact thermoelectric mini-fridge with heat/cool toggle. The most-mentioned dedicated peptide-storage fridge in research community sources — fits ~20 vials and runs quietly.

View on Amazon →
BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)
Injection

BD Ultra-Fine 31G 0.3cc 5/16" Insulin Syringes (Box of 90)

0.3cc 31G syringes — each gradation marks 1 unit (vs 2 units on 1cc), making sub-50-unit peptide doses accurate. BD Ultra-Fine is the most widely-cited brand in peptide community sources.

View on Amazon →
Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped
Injection

Med-Pride Alcohol Prep Pads — Medical-Grade, Individually Wrapped

Medical-grade 70% isopropyl alcohol prep pads, individually wrapped and sterile single-use. Standard for cleaning vial stoppers and injection sites before sub-Q dosing.

View on Amazon →
CONTOUR NEXT GEN Glucose Meter All-In-One Kit
Tracking

CONTOUR NEXT GEN Glucose Meter All-In-One Kit

Ascensia's CONTOUR NEXT GEN — the most clinically-validated home glucose meter. Includes 20 test strips + lancing device. Tracks the blood-sugar response GLP-1 users care about, especially during dose escalation.

View on Amazon →

As an Amazon Associate, The Peptide Catalog earns from qualifying purchases.

Full catalog →

Frequently Asked Questions

What side effects did CJC-1295 Phase 1/2 trials report?
Phase 1 and 2 trials reported injection-site reactions and brief facial flushing as the most common events. IGF-1 elevation of 1.5-3x baseline was a pharmacologic finding (Teichman et al., PMID 16352683). No serious adverse events were reported at the studied doses.
Does CJC-1295 cause water retention?
Self-reported community data clusters around mild fluid retention — particularly in the hands and face — during the first 2-4 weeks at higher doses. The pattern is more pronounced with the DAC-modified version. Community sources commonly describe dose reduction or splitting per-dose amounts as the mitigation.
Why does CJC-1295 cause flushing?
Brief facial flushing is described in CJC-1295 Phase 1/2 trial reports and consistently in community sources. The mechanism is attributed to vasodilatory effects of the GHRH-pathway activation. The flush typically appears within 10-20 minutes of injection and resolves within 30 minutes.
Is CJC-1295 with DAC more risky than without?
The DAC version's covalent albumin binding produces sustained GH and IGF-1 elevation across 5-8 days versus the pulsatile pattern of the non-DAC version (PMID 16352683). Community reports describe more water retention and hand-tingling on DAC. Trial data is limited; head-to-head safety comparison has not been formally trialed.
When do trial protocols and community sources describe stopping CJC-1295?
Phase 1/2 protocols allowed dose-interruption for severe injection-site reactions and for IGF-1 elevations above protocol thresholds. Community sources describe dose reduction or pause when hand-tingling, facial fluid retention, or sleep disruption become intrusive.

References

Citation Topic PMID
Teichman et al., J Clin Endocrinol Metab (2006) CJC-1295 Phase 1/2 prolonged GH/IGF-1 stimulation 16352683
Jetté et al., Endocrinology (2005) CJC-1295 long-lasting GRF analog mechanism 15817669
Ionescu & Frohman, J Clin Endocrinol Metab (2006) Sustained GHRH effect on GH secretion via CJC-1295 16822960

For educational and research purposes only. This is not medical advice. CJC-1295 is not FDA-approved for any indication. Consult a healthcare provider before use.